Skip to content

NeoGenomics NEO Operating lease liabilities

Operating lease liabilities at other companies

Natera, Inc. logo
Natera, Inc.NTRA
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
Immunome logo
ImmunomeIMNM
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
Veracyte logo
VeracyteVCYT

Other financials

Income statement

See full
Revenue$186.7M+11.1%
Gross profit$80.9M+10.4%
Operating income-$18.2M+34.4%
Net income-$17.1M+34.0%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$146.1M-57.8%
Total debt$66.3M+5.3%
Total equity$828.8M-6.7%
Total assets$1.3B-15.9%

Cash flow

See full
Operating cash flow-$8.1M+67.9%
CapEx$5.0M+11.1%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$1.79B+98.5%
Enterprise value$1.71B+177%
P/S2.4×+1.1×

Profitability

See full
Gross margin43.2%-1.1pp
Operating margin-14.2%+1.1pp
Net margin-13.3%+2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-11.6%+6.2pp
Debt / equity0.1×0.0×
Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NeoGenomics's operating lease liabilities?
NeoGenomics (NEO) reported operating lease liabilities of -$1.3M in Q1 2026.
How has NeoGenomics's operating lease liabilities changed year-over-year?
NeoGenomics's operating lease liabilities decreased by 19.2% year-over-year, from -$1.09M to -$1.3M.
What is the long-term trend for NeoGenomics's operating lease liabilities?
Over 3 years (2021 to 2024), NeoGenomics's operating lease liabilities has grown at a -8.7% compound annual growth rate (CAGR), from -$7.88M to -$6M.